Trial reportNature medicine2025
Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N
Abstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Functional proteomic and phosphoproteomic profiling of routine FFPE CNS tumor tissue complements genomic and epigenomic characterization.Acta neuropathologica · 2026Article
- Accelerating discovery: Transformative clinical trial models in neuro-oncology.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- The Invasive Margin of Glioblastoma as a Molecular Ecosystem: Spatial Heterogeneity, Tumor-Host Interactions, and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Exploring the landscape of targetable alterations in patients with glioblastoma.Nature reviews. Clinical oncology · 2026Review
- Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening.Neuro-oncology · 2026Article
- Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.Nature cancer · 2026Article
- Cystic glioblastoma is associated with alterations of KDR and the Rb pathway: a single-center retrospective analysis.Acta neuropathologica communications · 2026Article
- Brain Cancer: Molecular Alterations and Emerging Trends in Neuropharmacology.International journal of molecular sciences · 2026Review
- Conditional survival in glioblastoma: The evolution of prognostic factors over time.International journal of cancer · 2026Article
- Phosphorylated mTOR immunohistochemistry-guided use of temsirolimus in recurrent IDH-wildtype glioblastoma: a real-world retrospective series.Journal of cancer research and clinical oncology · 2026Article
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.International journal of molecular sciences · 2026Review
- Repeat resection for recurrent glioblastoma - does timing matter?Journal of neuro-oncology · 2026Article
- Critical role of cell competition in gliomagenesis.bioRxiv : the preprint server for biology · 2026Article
- Local Nanomedicine and Nano-Enabled Biomaterials After Glioblastoma Resection.International journal of nanomedicine · 2026Review
- A precision medicine umbrella trial to nominate promising therapies for glioblastoma.Neuro-oncology · 2026Article
- Targeting molecular vulnerabilities in glioblastoma.Nature medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Wolfgang WickNeurology, University Clinic Heidelberg, Heidelberg University & German Cancer Consortium (DKTK) and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany. wolfgang.wick@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0002-6171-634X
Lisa-Marie LanzNCT Trial Center, University Clinic Heidelberg, Heidelberg University & German Cancer Research Center, Heidelberg, Germany.
Antje WickNeurology, University Clinic Heidelberg, Heidelberg University & German Cancer Consortium (DKTK) and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany.
Inga HartingNeuroradiology, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Susan DettmerNCT Trial Center, University Clinic Heidelberg, Heidelberg University & German Cancer Research Center, Heidelberg, Germany.
Abigail K SuwalaNeuropathology, University Clinic Heidelberg, Heidelberg University & German Cancer Research Center, Heidelberg, Germany.
Ralf KetterNeurosurgery, Saarland University, Homburg, Germany.
Ghazaleh TabatabaiDepartment of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University, Tübingen, Germany.ORCID http://orcid.org/0000-0002-3542-8782
Corinna SeligerNeurology, University Clinic Heidelberg, Heidelberg University & German Cancer Consortium (DKTK) and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany.
Martin GlasDivision of Clinical Neurooncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Michael C BurgerDr. Senckenberg Institute of Neurooncology, Goethe University Frankfurt and Goethe University Hospital, Frankfurt, Germany.ORCID http://orcid.org/0000-0002-6927-0987
Marco TimmerDepartment of Neurosurgery, University Hospital Cologne, Cologne, Germany.
Florian A RingelNeurosurgery, University Medicine Mainz, Mainz, Germany.
Iris MildenbergerGerman Cancer Consortium (DKTK) & CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0009-0008-8825-4908
Walter J Schulz-SchaefferNeuropathology, Saarland University, Homburg, Germany.ORCID http://orcid.org/0000-0001-5886-2322
Frank WinklerNeurology, University Clinic Heidelberg, Heidelberg University & German Cancer Consortium (DKTK) and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-4892-6104
Laila KönigDepartment of Radiation Oncology, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Christel Herold-MendeDivision of Experimental Neurosurgery, Neurosurgery Clinic, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-1915-745X
Andreas EisenmengerNCT Trial Center, University Clinic Heidelberg, Heidelberg University & German Cancer Research Center, Heidelberg, Germany.
Stefan M PfisterHopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Division of Pediatric Neurooncology, Heidelberg University Hospital, Department of Pediatric Hematology and Oncology, National Center for Tumor Dieseases (NCT), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-5447-5322
Mirjam RenovanzDepartment of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University, Tübingen, Germany.
Martin BendszusNeuroradiology, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Felix SahmNeuropathology, University Clinic Heidelberg, Heidelberg University & German Cancer Research Center, Heidelberg, Germany. felix.sahm@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0001-5441-1962
Michael PlattenGerman Cancer Consortium (DKTK) & CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-4746-887X
Tobias KesslerNeurology, University Clinic Heidelberg, Heidelberg University & German Cancer Consortium (DKTK) and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-8350-7074
Funding
Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) HIPO 2-K25 and 2-K32RDeutsche Forschungsgemeinschaft (German Research Foundation) SFB 1389Deutsche Krebshilfe (German Cancer Aid) 70111980
Abstract
Advances in molecular understanding and diagnostic precision of glioblastoma enable the identification of key genetic alterations in a timely manner and, in principle, allow treatments with targeted compounds based on molecular markers. Here we report the results of the phase 1/2 umbrella trial NCT Neuro Master Match (N
Indexed as
Brain NeoplasmsGlioblastomaMolecular Targeted TherapyAdultAgedFemaleHumansMaleMiddle AgedPiperidinesPyridinesSirolimusTemozolomidePiperidinesPyridinesSirolimusTemozolomide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.